Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50-80
SponsorUniversity Hospital, Bonn

About this trial

α-Synucleinopathies, including Parkinson's disease and dementia with Lewy bodies, are the second most common neurodegenerative diseases. In addition to progressive motor deterioration, cognitive decline is a key element of the non-motor symptom complex of these diseases. Isolated rapid eye movement (REM) sleep behavior disorder (iRBD) indicates an early stage of α-synucleinopathies, even before relevant motor or cognitive disorders are present. Therapeutic interventions in individuals with iRBD therefore have great preventive potential. In particular, increasing physical activity could have a relevant effect on neurodegenerative processes, including the preservation of cognitive functions.

The aim of the study is therefore to investigate the effects of increased physical activity in everyday life on cognitive functions in individuals with iRBD. In this randomized, double-blind, actively controlled study, an increase in physical activity will be implemented over a period of one year with the help of a motivational smartphone application. The intervention and control conditions are the same as those used in the Slow-SPEED trials, making the connection between the trials concrete. The primary outcome parameter is the change in cognitive performance in a neuropsychological test battery over one year.

Eighty individuals with iRBD and 50 age- and gender-matched individuals are being recruited at the University Hospital Bonn and the "Deutsches Zentrum für Neurodegenerative Erkrankungen" (DZNE) Bonn (German branch only). In addition to classic neuropsychological tests as the primary endpoint, magnetic resonance imaging (MRI) and blood-based markers of brain aging are being examined as secondary endpoints. This study is in close collaboration with the Slow-SPEED study (https://clinicaltrials.gov/study/NCT06993142). In addition, selected data from three separate trials-Alpha-Fit, Slow-SPEED-NL, and a sister trial in Austria currently in preparation-are planned to be synthesized into a meta-analysis.

Eligibility criteria

Qualifiers

Age: 50-80 years

Polysomnographically confirmed diagnosis of iRBD

Maximum of 120 minutes of sports/outdoor activities per day

Less than an average of 10,000 steps per day during the 4-week eligibility and baseline phase

Disqualifiers

Relevant cardiovascular diseases

Problems with dexterity or cognitive impairments that make it difficult to use a smartphone

Cognitive impairments that limit the ability to make informed decisions and consent to participate in the study

Ownership of one of the following devices: Huawei P8 Lite, Huawei P9 Lite, Xiaomi Mi 6, Huawei P20 Lite (FitBit is not compatible)

Trial design

Treatments tested in this trial

  • Increase of physical activity volume and intensity with the use of a motivational smartphone application

Treatment groups

130 Participants
are divided into 2 treatment groups

Sponsors and collaborators

University Hospital, Bonn

Lead sponsor

Radboud University Medical Center

Collaborator

Medical University Innsbruck

Collaborator

IJsfontein B.V., Netherlands

Collaborator

Synaptikon GmbH

Collaborator

Parkinson Stiftung

Collaborator